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ABSTRACT: Next-generation sequencing (NGS) has
proven to be an exceptionally powerful tool for studying
genetic variation and diﬀerences in gene expression
proﬁles between cell populations. However, these
population-wide studies are limited by their inability to
detect variation between individual cells within a
population, inspiring the development of single-cell
techniques such as Drop-seq, which add a unique barcode
to the mRNA from each cell prior to sequencing. Current
Drop-seq technology enables capture, ampliﬁcation, and
barcoding of the entire mRNA transcriptome of individual
cells. NGS can then be used to sequence the 3′-end of
each message to build a cell-speciﬁc transcriptional
landscape. However, current technology does not allow
high-throughput capture of information distant from the
mRNA poly-A tail. Thus, gene proﬁling would have much
greater utility if beads could be generated having multiple
transcript-speciﬁc capture sequences. Here we report the
use of a reversible chain blocking group to enable synthesis
of DNA barcoded beads having capture sequences for the
constant domains of the T-cell receptor α and β chain
mRNAs. We demonstrate that these beads can be used to
capture and pair TCRα and TCRβ sequences from total T-
cell RNA, enabling reverse transcription and PCR
ampliﬁcation of these sequences. This is the ﬁrst example
of capture beads having more than one capture sequence,
and we envision that this technology will be of high utility
for applications such as pairing the antigen receptor chains
that give rise to autoimmune diseases or measuring the
ratios of mRNA splice variants in cancer stem cells.
The widespread availability of next-generation sequencing(NGS) instruments has enabled researchers around the
world to examine organisms at unprecedented levels of detail at
low cost, resulting in a rapid escalation of NGS-based studies.1
Current technologies generally require large amounts of
template material, which is produced from samples containing
millions of cells. While data generated using this approach give
a view of the population-wide characteristics of these cells, it
provides no mechanism for linking information to individual
cells. As a result, it is not possible to directly examine the
distribution of variation across large populations of cells within
a sample. This important limitation means that variation that is
present at a low frequency within a population cannot be easily
discriminated from sequencing noise. Furthermore, population-
based methods are incapable of directly examining how the
relative frequency of variation within a population of cells
ﬂuctuates over time. These deﬁciencies of NGS technology
pose a particularly large challenge for research examining cancer
stem cells, which occur at a low frequency in tumors, but are
thought to be central to tumor survival and treatment escape.2
Recently, high-throughput ﬂuidics-based systems such as
Drop-seq have been reported in which individual cells are
incubated with an mRNA capture bead in nanoliter droplets,
enabling downstream sequencing of mRNA on a single-cell
level.3 This method has allowed signiﬁcant progress in
circumventing the limitations of population-wide studies, but
it remains incompatible with the preferred short read length
sequencing platforms for many sequences where critical
information is distant from the 3′-end of the message.
Additionally, the current technology only enables capture of a
single mRNA sequence (usually the poly-A tail of mRNA). The
ability to use two or more capture sequences would be of
signiﬁcant value, for example in measuring the ratio of
diﬀerentially spliced messages in individual cancer stem cells,
or obtaining the paired sequences of α and β antigen receptor
chains.
The antigen receptors on individual lymphocytes control
their speciﬁcity and are critical components in disease
outcome.4 These receptors are created by somatic gene
rearrangements at two loci on diﬀerent chromosomes to
produce the antibody-like αβ T-cell receptor (TCR) or γδ
TCR. The αβ TCR is of particular interest, as this receptor is
believed to orchestrate the adaptive immune response. The
critical determinant of antigen speciﬁcity is the rearrangement
of variable (V), diversity (D), and joining (J) segments that
make up the complementarity determining regions (CDRs),
and each T-cell clone has a unique set of CDR sequences.5 The
antigen receptor V(D)J sequence for each chain lies adjacent to
a locus-speciﬁc constant domain, enabling capture from the
total cellular RNA using primers speciﬁc for this sequence.6
Subsequent primer extension and PCR ampliﬁcation can then
allow complete chain sequence assembly from short NGS
reads. Obtaining the paired α and β chain antigen receptor
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sequences for all of the lymphocytes in a clinical sample,
combined with their abundance and activation status, would
allow powerful systems level examination of human pathologies
and disease, and there is much interest in this area.7
Unfortunately, current single-cell analyses of this type are
extremely laborious, constraining throughput to hundreds of
cells, and therefore these studies only scratch the surface of this
valuable trove of information.
The ability to obtain paired sequence information for antigen
receptor chains within large clinical samples using method-
ologies such as Drop-seq would be a game changing
technology. However, this requires the construction of capture
beads having two diﬀerent primer sequences attached to bead-
speciﬁc unique barcodes that allow chain reconstruction from
short read-length NGS platforms. Here we overcome this
challenge using a novel phosphoramidite monomer that
reversibly blocks chain extension to enable divergent synthesis
of two primer sequences on each barcoded bead. We
demonstrate that two diﬀerent capture sequences can be built
onto a single bead, enabling speciﬁc capture and ampliﬁcation
of mRNAs encoding the α and β chains of the αβ TCR.
In principle, capture beads having two diﬀerent primer
sequences could be generated by chemical attachment of the
primers to beads. However, a critical component of single-cell
analysis techniques is the use of unique barcodes on each bead,
located upstream from the primer sequence. This enables the
>108 reads acquired from NGS to be regrouped into
populations arising from each individual cell.3 The barcoded
beads are generated using split-pool combinatorial synthesis,
and thus the primer sequences must be synthesized directly
onto the barcode sequence, such that the entire sequence is
ampliﬁed and read in NGS. An additional consideration for the
capture beads is that the DNA must be synthesized in the
“reverse” 5′−3′ direction, as this provides the 3′-terminus that
is needed for enzymatic primer extension after mRNA capture.
We envisioned the synthetic strategy shown in Figure 1, in
which split-pool synthesis would be used to generate barcoded
beads, and these would then be reacted with a mixture of 5′
phosphoramidite monomers having two diﬀerent protecting
groups at the 3′-position. This would enable selective
deprotection of half of the oligonucleotides and synthesis of
the ﬁrst primer sequence, followed by a second deprotection
and primer synthesis. The ﬁrst monomer could have the typical
dimethoxytrityl (DMT) protecting group, which is removed
under mildly acidic conditions. But, the second monomer
requires a protecting group having the following characteristics:
(1) stable to DMT deprotection conditions; (2) stable to
conditions used for oligonucleotide synthesis; (3) deprotected
under conditions compatible with DNA oligonucleotides. A
search of the literature revealed no examples of 3′-protected
phosphoramidite monomers that would meet these require-
ments. However, our interest was piqued by previous reports
using a 2′-levulinyl protecting group for the synthesis of
branched oligonucleotides.8 This protecting group appeared to
meet the requirements outlined above, as it had been shown to
be stable to the conditions used for RNA synthesis and is
deprotected using aqueous hydrazine, which is nondamaging to
oligonucleotides and orthogonal to the acidic DMT depro-
tection conditions.
As shown in Figure 2a, we synthesized 3′-OLev thymine
phosphoramidite 2 from commercially available 1 using
standard protocols. We then carried out a synthesis of short
polyT sequences to test the compatibility of 2 with our
divergent oligonucleotide synthesis protocol. To mimic syn-
thesis of the barcode region, we performed four thymine
monomer coupling steps on all beads. We then added a 1:1
mixture of 3′-ODMT monomer 3 and 3′-OLev monomer 2.
The DMT group was then removed, and the deprotected
oligonucleotide chains coupled with a ﬂuorescein phosphor-
amidite. Next, the Lev group was removed using aqueous
hydrazine, and the resulting deprotected oligonucleotide chains
were coupled with an additional thymine monomer. Both
oligonucleotide chains were then cleaved from the beads and
analyzed by HPLC. As shown in Figure 2b, the ratio between
T5-FAM DNA (arising from addition of 3) and T6 DNA
(arising from addition of 2) is very close to 1:1, demonstrating
that the two diﬀerent monomers are added to a growing
oligonucleotide chain with nearly equal eﬃciency. Additionally,
the high purity of the DNA products obtained indicates that the
Lev protecting group is not removed during DMT removal or
the subsequent coupling step and that deprotection of the Lev
group does not damage the DNA molecules.
Having established that Lev can function as a DNA-
compatible orthogonal protecting group, we next sought to
generate dual-primer beads for capture and ampliﬁcation of the
mRNAs encoding the α and β chains of the T-cell antigen
receptor. Using the same synthetic protocol as described above
for the test beads, we synthesized beads capable of targeting
both the T-cell receptor alpha chain (TCRα) and beta chain
(TCRβ) mRNAs. Speciﬁcally, the capture sequences attached
to the beads are complementary to the TCRα and TCRβ
constant regions (TRAC and TRBC). To test the ability of the
capture beads to pull down TCR mRNA, the beads were mixed
with total RNA isolated from a known T cell clone (clone
GDB4). Unbound RNA was removed by washing, and the
bead-bound RNA was subjected to a reverse transcription
reaction in which the DNA oligonucleotides attached to the
beads served as primers for the synthesis of bead-bound cDNA.
Figure 1. Beads can be synthesized having a unique barcode, and then
a 1:1 mixture of 3′-DMT and 3′-Lev phosphoramidites are added to
enable stepwise synthesis of two diﬀerent oligonucleotides on each
bead.
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PCR ampliﬁcation of the cDNA was then performed using
primers complementary to the known sequence of the TCR α
and β chain transcripts in the GDB4 clone. As a control, all of
the above steps were also carried out using “raw” beads, on
which no DNA had been synthesized. Figure 3 shows an
agarose gel image of the PCR product from each reaction. As
anticipated, we observe ampliﬁcation of the TCRα and TCRβ
sequences when using the capture beads, but not with the raw
beads. The bands corresponding to the PCR products were
excised from the gel and subjected to Sanger sequencing. The
sequencing results shown in Figure S1 are consistent with the
known TCRα and TCRβ sequences in the GDB4 clone,
conﬁrming the ability of the capture beads to pull down TCR
mRNA.
In conclusion, we have demonstrated that beads containing
unique oligonucleotide barcodes followed by two independent
oligonucleotide capture sequences can be produced. These
beads can be used to capture two diﬀerent speciﬁc target
sequences, which has high utility in cases such as the T-cell
antigen receptor, where receptor chain pairing is critical for
determination of antigen speciﬁcity, but is highly variable at the
single cell level. Importantly, each bead has approximately 5000
copies of each capture sequence, which provides redundancy in
the sequencing process to discriminate real polymorphisms
from transcriptional or sequencing errors (Figure 4). The key
to achieving synthesis of the two diﬀerent oligonucleotide
sequences on a single bead is use of a 3′-Lev-protected
phosphoramidite, which is stable to the conditions used for
Figure 2. (a) Synthesis of Lev-protected monomer 2. (b) Chemical
structure of DMT-protected monomer 3. (c) HPLC traces of test
sequences synthesized in tandem on the same beads. Black trace shows
product cleaved from beads. Blue and red traces show individually
synthesized products arising from coupling of 2 and 3, respectively.
Figure 3. RNA from lysed T cells was incubated with capture beads
having sequences complementary to the constant region of TCRα and
TCRβ. Captured RNA was reverse transcribed and PCR ampliﬁed,
and then it was resolved using gel electrophoresis and visualized by
ethidium bromide staining. PCR reactions from the capture beads
show ampliﬁcation of TCRα and TCRβ sequences. As a control, all of
the above steps were performed using raw beads (no oligos attached)
and show no PCR product. The size (in base pairs) of the smallest ﬁve
bands in the DNA ladder are indicated to the left of the ﬁrst gel image.
Figure 4. Multiple copies of α and β chain mRNAs can be captured
from each cell by individual beads. Alignments of redundant
sequencing reads from each bead allow discrimination between true
polymorphisms and sequencing or transcriptional errors.
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DMT deprotection and oligonucleotide synthesis, and can be
subsequently removed without damaging the newly formed
oligonucleotides. While the current study only utilized a single
diﬀerential protection step, we envision that the divergent
DMT/Lev protection step could be used iteratively to generate
beads having larger numbers of unique DNA capture
sequences. This synthesis scheme may also be used to produce
capture reagents that can be used as biological probes when
linked to sequences that include molecular dyes that can be
speciﬁcally visualized or quenched.
The immense diversity of the adaptive immune system relies
on production of three antigen receptor types, on both B-cells
and T-cells, that are synthesized from transcripts that have
undergone germline rearrangements. Identifying these germline
rearrangements is only possible through direct sequencing of
the corresponding DNA or mRNA. As our understanding of
the complexity of the adaptive immune response continues to
expand, abhorrent immune responses have been identiﬁed as
the basis for several diseases.9 These diseases can arise from a
single clone, and thus the ability to obtain paired sequence
information for antigen receptor α and β chains at the single
cell level could be transformative in identifying these disease
causing autoimmune clones. The research reported here
provides the tools necessary to undertake these experiments
and demonstrates the feasibility of this approach by capturing,
amplifying, and sequencing the α and β chains for a single T-
cell receptor clone. Future studies will be aimed at utilizing our
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